admin – Page 2823 – Get News Story

IgA Nephropathy Therapeutic Market Expected to Witness Significant Growth By 2034, Driven by Recent FDA Approval and Novel Therapeutics | DelveInsight

“IgA Nephropathy Market Insight, Epidemiology And Market Forecast – 2034”

The IgA Nephropathy (IgAN) treatment market is poised for substantial growth, driven by the introduction of innovative therapies and the increasing prevalence of this chronic kidney disease. Leading IgAN companies, including Calliditas Therapeutics AB, Travere Therapeutics, Inc., Omeros, Novartis Pharmaceuticals, Chinook Therapeutics, Inc., and Vera Therapeutics, among others, are at the forefront of transforming the IgAN treatment landscape.

DelveInsight’s “IgA Nephropathy Market Insight, Epidemiology And Market Forecast – 2034” report provides an extensive analysis of IgA nephropathy (IgAN), including historical and forecasted epidemiology data, current treatment practices, emerging therapies, and market projections across the 7MM (United States, Germany, France, Italy, Spain, United Kingdom, and Japan). The report indicates that the IgA Nephropathy market is anticipated to grow at a significant CAGR during the study period (2020-2034), driven by increasing disease awareness, improved diagnostic capabilities, and the launch of novel therapeutic options targeting specific pathways involved in IgAN pathogenesis.

This market expansion reflects growing recognition of IgAN as a significant cause of end-stage renal disease (ESRD) globally and the urgent need for effective disease-modifying treatments beyond conventional supportive care.

IgA nephropathy, also known as Berger disease, is a chronic kidney disorder characterized by the deposition of immunoglobulin A (IgA) antibodies in the glomeruli—the tiny filtering units within the kidneys. This abnormal buildup triggers inflammation and progressive damage, impairing the kidneys’ ability to filter waste and excess fluid from the blood. Over time, IgA nephropathy can lead to chronic kidney disease or even kidney failure in a significant subset of patients, making it one of the most common causes of glomerulonephritis worldwide.

Download the IgA nephropathy market report to understand which factors are driving the IgA nephropathy therapeutic market @ IgA Nephropathy Market Trends.

According to DelveInsight’s epidemiological analysis, the total diagnosed prevalent population of IgA Nephropathy in the 7MM comprised approximately 400K cases in 2023. Japan accounted for the highest proportion of IgAN diagnosed prevalent cases, representing about 45% of the total patient population across the studied regions. Furthermore, the data reveals a notable gender disparity, with IgA nephropathy showing male predominance in the United States in 2023. This epidemiological profile underscores the substantial patient population that could benefit from emerging targeted therapies, thereby driving market growth in the forecast period.

Discover evolving trends in the IgAN patient pool forecasts @ IgAN Epidemiology Analysis.

The IgA nephropathy pipeline is robust, featuring multiple promising candidates in late-stage development that target various pathophysiological mechanisms. Current clinical development programs focus on innovative approaches, including complement pathway inhibition, B-cell modulation, targeted immunosuppression, and novel anti-inflammatory agents. These emerging therapies address the multifaceted nature of IgAN pathogenesis and offer improved efficacy, safety profiles, and quality of life outcomes compared to conventional treatments. The diversification of therapeutic approaches reflects growing understanding of the complex immunological mechanisms underlying IgAN and represents a paradigm shift toward precision medicine in nephrology.

The IgA nephropathy treatment landscape has witnessed significant advancements in recent years, with several breakthrough approvals reshaping clinical practice and further expanding this significant market. In September 2024, Travere Therapeutics achieved a major milestone with the full FDA approval of FILSPARI to slow the decline in kidney function in adults with primary IgA nephropathy. This approval followed an earlier accelerated approval based on proteinuria reduction, with full approval supported by positive long-term data from the PROTECT Study demonstrating sustained clinical benefits. Additionally, FILSPARI received conditional marketing authorization from the European Commission in April 2024 for treating adults with primary IgAN with significant proteinuria.

Discover evolving trends in the IgA Nephropathy treatment landscape @ IgA Nephropathy Therapies Market.

Moreover, in April 2025, Novartis (SWX: NOVN) received FDA accelerated approval for VANRAFIA, making it the first and only selective endothelin receptor antagonist approved to reduce proteinuria in adults with primary IgA nephropathy. This approval is based on the ongoing Phase III ALIGN study, which showed that patients receiving Vanrafia in combination with a RAS inhibitor experienced a clinically meaningful and statistically significant proteinuria reduction of 36.1% (P<0.0001) compared to placebo.

In March 2025, Arrowhead Pharmaceuticals’ RNAi therapy ARO-C3 demonstrated promising results in a Phase I/II trial for IgA nephropathy, with a mean 89% reduction in complement protein C3 and a 41% decrease in proteinuria (UPCR) after 24 weeks. Administered subcutaneously every three months, the treatment showed sustained suppression of alternative complement pathway activity (≥87% C3 reduction) and was well-tolerated, with only mild side effects like headaches and coughs reported. Full data will be presented at a medical conference in late 2025, positioning ARO-C3 as a potential quarterly treatment targeting the root cause of IgAN.

Also, the European Commission converted accelerated approval of FILSPARI (Travere Therapeutics) to standard approval in April 2025.

Discover recent advancements in the IgA Nephropathy treatment landscape @ IgA Nephropathy Recent Developments.

Despite therapeutic advances, significant unmet needs persist in the IgA nephropathy treatment landscape. These include the need for earlier disease detection, biomarkers to predict disease progression and treatment response, and therapies that can reverse existing kidney damage rather than merely slowing disease progression. Moreover, improving access to specialized care and novel therapies remains challenging, particularly in regions with limited healthcare resources. DelveInsight’s analysis highlights that addressing these unmet needs will be crucial for optimizing patient outcomes and maximizing the market potential for emerging IgAN therapies.

Looking ahead, the IgA nephropathy market is expected to witness transformative growth. The integration of biomarkers into clinical practice and the development of combination therapeutic strategies targeting multiple pathways simultaneously represent promising future directions. Additionally, ongoing research into the genetic and molecular determinants of IgAN susceptibility and progression may pave the way for personalized treatment approaches, further revolutionizing the management of this chronic kidney disease and enhancing long-term patient outcomes across the global IgAN landscape.

Table of Contents

1. Key Insights

2. Report Introduction

3. IgAN Market Overview at a Glance

4. Executive Summary

5. Key Events

6. Disease Background and Overview

7. Methodology

8. IgAN Epidemiology and Patient Population

9. IgAN Patient Journey

10. IgAN Marketed Drugs

11. IgAN Emerging Drugs

12. IgAN – 7MM Market Analysis

13. KOL Views

14. IgAN Unmet Needs

15. SWOT Analysis

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: IgA Nephropathy Therapeutic Market Expected to Witness Significant Growth By 2034, Driven by Recent FDA Approval and Novel Therapeutics | DelveInsight

Ocular Hypertension Market Set for Steady Growth Through 2034, Driven by Novel Therapies and Aging Population Demographics | DelveInsight

“Ocular Hypertension Market Insight, Epidemiology And Market Forecast – 2034”

The ocular hypertension market is experiencing steady expansion, driven by increasing prevalence of chronic conditions, an aging population, and breakthrough therapies from key pharmaceutical players, including Bausch + Lomb, Alcon, Santen Pharmaceutical, AbbVie, Nicox, Kowa, Qlaris Bio, and Noveome Biotherapeutics, among others.

DelveInsight’s “Ocular Hypertension Market Insight, Epidemiology And Market Forecast – 2034” report delivers an in-depth understanding of the ocular hypertension treatment market, historical and forecasted epidemiology, as well as market trends across the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report comprehensively evaluates the current treatment landscape, emerging therapies, market share of individual treatments, and ocular hypertension market forecasts through 2034, providing crucial insights for stakeholders in the ocular hypertension therapeutic area.

According to DelveInsight’s analysis, the ocular hypertension market in the 7MM is expected to grow at a CAGR of approximately 3% during the forecast period from 2025 to 2034, driven by the introduction of novel therapies such as NCX 470, QLS-111, and ST266, alongside a growing aging population.

Download the Ocular Hypertension Market report to understand which factors are driving the ocular hypertension therapeutic market trends.

According to DelveInsight’s estimates, in 2024, there were approximately 13 million cases diagnosed with ocular hypertension in the 7MM, with a total of 21 million prevalent cases. The United States accounted for 41% of the diagnosed cases, while EU4 and the UK represented 38% and Japan represented 21% of the cases. Both prevalence and diagnostic rates are projected to increase over the forecast period (2025–2034).

The DelveInsight report further categorizes the ocular hypertension patient population into several groups for analysis, including gender-specific prevalence and age-specific prevalence cases. In 2024, females were more affected by ocular hypertension in the US compared to males. Additionally, Japan saw the highest prevalence of ocular hypertension among individuals aged 80 and above, followed by those in the lower age groups.

Discover evolving trends in the Ocular Hypertension patient pool forecasts.

The current ocular hypertension treatment landscape involves both pharmacological and surgical therapies, with the market segmented into various classes: prostaglandin analogs (PGAs), beta-blockers, alpha-agonists, carbonic anhydrase inhibitors, RHO kinase inhibitors, and combination therapies. VYZULTA (latanoprostene bunod ophthalmic solution) by Bausch + Lomb represents a significant advancement, offering a dual mechanism of action as a prostaglandin analog designed to manage IOP in patients with open-angle glaucoma or ocular hypertension.

RHOPRESSA (netarsudil ophthalmic solution) by Alcon/Santen Pharmaceutical, a 0.02% Rho kinase inhibitor, lowers intraocular pressure by increasing aqueous humor outflow through the trabecular meshwork, reducing aqueous humor production, and lowering episcleral venous pressure. Meanwhile, DURYSTA (bimatoprost implant) by AbbVie delivers a biodegradable implant containing 10 µg of bimatoprost via a single intracameral administration.

The ocular hypertension pipeline shows promising developments with several novel treatments in clinical stages. NCX 470 by Nicox/Kowa is an innovative eye drop formulation combining nitric oxide and bimatoprost to lower IOP through dual mechanisms, with topline results from the Denali Phase III trial expected in the second half of 2025. QLS-111 by Qlaris Bio, based on an ATP-sensitive potassium channel modulator platform, has shown persistent IOP reduction without causing hyperemia, with two US Phase II trials initiated in April 2024. ST266 by Noveome Biotherapeutics, a cell-free biologic containing hundreds of proteins and factors involved in cellular healing and neuroprotection, has demonstrated anti-inflammatory and neuroprotective effects in preclinical studies.

Recent developments highlight the dynamic nature of the ocular hypertension treatment landscape. The US NDA for NCX 470 is expected to be submitted in H1 2026, while Qlaris Bio secured USD 24 million in Series B funding to support QLS-111 development. Further clinical milestone updates and regulatory submissions are anticipated throughout the forecast period.

Discover recent advancements in the Ocular Hypertension treatment landscape.

The ocular hypertension treatment market is highly competitive, with major players including Bausch + Lomb, Alcon, Santen Pharmaceutical, AbbVie, Nicox, Kowa, Qlaris Bio, Noveome Biotherapeutics, and other pharmaceutical companies advancing innovative therapies through robust R&D and strategic partnerships. The market landscape continues to evolve with companies pursuing clinical trials and strategic partnerships to introduce innovative treatment approaches and expand their market share.

Looking ahead, the ocular hypertension market faces challenges related to the variability in angle configurations, necessitating varied surgical approaches for effective intraocular pressure management. However, future treatment opportunities are expanding with a focus on pharmacological advancements and innovative delivery methods, including neuroprotection approaches to preserve ocular health. New therapies such as rho kinase inhibitors and nitric oxide-donating PGAs focus on improving aqueous humor outflow, specifically targeting the trabecular meshwork.

DelveInsight’s analysis underscores that several unmet needs remain in ocular hypertension management, prompting continued innovation in treatment approaches. As the market evolves with novel therapeutic mechanisms and improved delivery systems, the ocular hypertension market is positioned for steady growth and therapeutic advancement, driven by demographic trends and ongoing clinical development activities.

Table of Contents

1. Key Insights

2. Report Introduction

3. Ocular Hypertension Market Overview at a Glance

4. Ocular Hypertension Market: Future Perspective

5. Executive Summary of Ocular Hypertension

6. Key Events

7. Ocular Hypertension Background and Overview

8. Ocular Hypertension Market Epidemiology and Patient Population

9. Ocular Hypertension Patient Journey

10. Ocular Hypertension Marketed Drugs

11. Ocular Hypertension Emerging Drugs

12. Ocular Hypertension: Seven Major Market Analysis

13. Key Opinion Leaders’ Views

14. Ocular Hypertension Market Unmet Needs

15. SWOT Analysis

16. Reimbursement and Market Access

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Ocular Hypertension pipeline insight provides comprehensive insights about the Ocular Hypertension pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Ocular Hypertension companies, including Santen Pharmaceutical, Nicox Ophthalmics, Inc., Allysta Pharmaceuticals, Qlaris Bio, Ripple Therapeutics, Laboratoires Thea, Ocular Therapeutix, Inc., Otsuka Beijing Research Institute, Alcon Research, AbbVie, Glaukos Corporation, MediPrint Ophthalmics, and Ocuphire Pharma, among others.

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ocular Hypertension Market Set for Steady Growth Through 2034, Driven by Novel Therapies and Aging Population Demographics | DelveInsight

Mucopolysaccharidosis I Treatment Market Set for Robust Growth Through 2034, Driven by Emerging Gene Therapies and Pipeline Developments | DelveInsight

The Mucopolysaccharidosis I treatment market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and breakthrough therapies from key pharmaceutical players, including BioMarin Pharmaceutical, Sanofi, Orchard Therapeutics, Kyowa Kirin, JCR Pharmaceuticals, REGENXBIO, Nippon Shinyaku, and Immusoft, among others.

DelveInsight’s “Mucopolysaccharidosis Type I Treatment Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the MPS I treatment market, historical and forecasted epidemiology, as well as market trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report comprehensively evaluates the current treatment landscape, emerging therapies, market share of individual treatments, and MPS I market forecasts through 2034, providing crucial insights into the MPS I therapeutic landscape.

According to DelveInsight’s analysis, the Mucopolysaccharidosis I Market in the 7MM was valued at approximately USD 145 million in 2024. Over the forecast period from 2025 to 2034, this market is projected to grow at a CAGR of 8.0%, driven by the launch of innovative Mucopolysaccharidosis I Therapies, including OTL-203, Lepunafusp alfa (JR-171), and RGX-111.

Download the Mucopolysaccharidosis I Market report to understand which factors are driving the Mucopolysaccharidosis I therapeutic market trends.

Epidemiology Insights Reveal Significant Patient Population

According to DelveInsight’s estimates, in 2024, there were approximately 660 Mucopolysaccharidosis I diagnosed prevalent cases in the 7MM. Of these, EU4 and the UK accounted for the largest cases with nearly 60% of the total Mucopolysaccharidosis I cases across 7MM, while the United States accounted for 36% of the cases with approximately 240 cases, and Japan represented 4% of the cases with around 20 cases.

In 2024, the UK reported the highest number of Mucopolysaccharidosis I Diagnosed Prevalent Cases among EU4 and the UK, with approximately 110 cases. Italy followed with nearly 75 cases, while Spain recorded the lowest diagnosed prevalent cases, with nearly 60 cases.

The DelveInsight report further categorizes the Mucopolysaccharidosis I patient population into severity-specific groups, differentiating between Hurler syndrome, Hurler-Scheie syndrome, and Scheie syndrome, with Hurler syndrome representing the most severe form affecting an estimated 1 in every 100,000 newborns.

Discover evolving trends in the Mucopolysaccharidosis I patient pool forecasts through epidemiological analysis.

Current Treatment Landscape Dominated by Single Therapy

Currently, in the Mucopolysaccharidosis I market, BioMarin Pharmaceutical and Sanofi are the only players, offering ALDURAZYME (laronidase). This Enzyme replacement therapy (ERT) is approved for patients with Hurler and Hurler-Scheie forms of MPS I, as well as those with the Scheie form who experience moderate to severe symptoms. ALDURAZYME is a recombinant form of the human enzyme IDUA and was first approved in the US in April 2003, followed by EU4 and the UK in June 2003, and Japan in 2006.

As per the estimates, among the current Mucopolysaccharidosis I Treatment options, ALDURAZYME hold the largest Mucopolysaccharidosis I drugs market share, generating approximately USD 145 million in revenue in 2024 across the 7MM. Although its patent has expired, no biosimilar or alternative biologic has been approved yet, highlighting a significant gap in treatment options for MPS I patients.

Promising Pipeline Developments Signal Market Transformation

The Mucopolysaccharidosis I pipeline is robust and promising, with several novel treatments in development addressing critical unmet needs. OTL-203, developed by Orchard Therapeutics and Kyowa Kirin, is a one-time gene therapy for MPS IH, using a patient’s own hematopoietic stem and progenitor cells. These cells are genetically modified ex vivo with a lentiviral vector carrying functional IDUA complementary DNA, restoring enzyme expression and reducing GAG accumulation. The therapy is currently in Phase III trials in North America and Europe, with anticipated US application in 2028 and potential approval in 2029 with priority review.

Lepunafusp alfa (JR-171), developed by JCR Pharmaceuticals, represents an advanced ERT designed to address central nervous system complications in MPS I. This recombinant fusion protein combines an antibody targeting the human transferrin receptor with IDUA, efficiently crossing the Blood-Brain Barrier through transferrin receptor-mediated transcytosis. The therapy has completed a 13-week Phase I/II clinical trial in Japan and the US, with an extension study ongoing.

RGX-111, developed by REGENXBIO and Nippon Shinyaku, is an investigational gene therapy that delivers a functional IDUA gene directly to the CNS, promoting enzyme production in brain cells. This approach aims to slow or prevent cognitive decline and neurological impairments associated with MPS I. Recent developments show promising biological activity and safety in ongoing Phase I/II trials.

Discover recent advancements in the Mucopolysaccharidosis I treatment landscape through ongoing clinical development programs.

Future Opportunities

The future of MPS I treatment is poised for significant advancements, driven by ongoing research and innovative therapies. Emerging treatments have the potential to address unmet needs, improve effectiveness, and enhance outcomes. As research progresses, integrating novel strategies will lead to a more comprehensive and effective approach to managing MPS I in the future.

Looking ahead, there is a significant need for new Mucopolysaccharidosis I treatments, as current therapies have limitations, including boxed warnings. The promising pipeline, including OTL-203, Lepunafusp alfa (JR-171), RGX-111, and Iduronicrin genleukocel-T (ISP-001), offers novel approaches that have the potential to reshape the treatment landscape by improving patient outcomes and reducing the limitations of existing treatments.

DelveInsight’s analysis underscores that despite current therapeutic limitations, substantial opportunities remain for developing more effective treatment options that can achieve better outcomes and improved quality of life for MPS I patients worldwide. As research continues and awareness grows, the Mucopolysaccharidosis I market is poised for remarkable expansion and therapeutic innovation.

Table of Contents

1. Key Insights

2. Report Introduction

3. Mucopolysaccharidosis I Market Overview at a Glance

4. Mucopolysaccharidosis I Market: Future Perspective

5. Executive Summary of Mucopolysaccharidosis I

6. Key Events

7. Mucopolysaccharidosis I Background and Overview

8. Mucopolysaccharidosis I Market Epidemiology and Patient Population

9. Mucopolysaccharidosis I Patient Journey

10. Mucopolysaccharidosis I Marketed Drugs

11. Mucopolysaccharidosis I Emerging Drugs

12. Mucopolysaccharidosis I: Seven Major Market Analysis

13. Key Opinion Leaders’ Views

14. Mucopolysaccharidosis I Market Unmet Needs

15. SWOT Analysis

16. Reimbursement and Market Access

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Mucopolysaccharidosis I pipeline insight provides comprehensive insights about the Mucopolysaccharidosis I pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Mucopolysaccharidosis I companies, including Takeda, BioMarin, Ultragenyx Pharmaceutical, Sarepta Therapeutics, Inventiva, GC Pharma, JCR Pharmaceuticals, REGENXBIO, Sangamo Therapeutics, Denali Therapeutics, ArmaGen, Chiesi, Eloxx Pharmaceuticals, Esteve, Greencross, Immusoft Corporation, and Paradigm Biopharmaceuticals Ltd., among others.

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Mucopolysaccharidosis I Treatment Market Set for Robust Growth Through 2034, Driven by Emerging Gene Therapies and Pipeline Developments | DelveInsight

Hepatitis D Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Hepatitis D Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Hepatitis D pipeline landscape. It covers the Hepatitis D pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatitis D pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Hepatitis D Pipeline. Dive into DelveInsight’s comprehensive report today! @ Hepatitis D Pipeline Outlook

Key Takeaways from the Hepatitis D Pipeline Report

In June 2025, Ribocure Pharmaceuticals AB announced clinical trial is to learn if drug RBD1016 works to treat chronic hepatitis D virus infection in adults. It will also learn about the safety of drug RBD1016. There will be 2 treatment groups – an active group (n=10) and a deferred active group (n=5), with participants allocated randomly. In the active group, participants will receive RBD1016. In the deferred active group, participants will receive 4 doses of placebo followed by deferred treatment with doses of RBD1016.
In June 2025, Vir Biotechnology Inc. conducted Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.
DelveInsight’s Hepatitis D Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Hepatitis D treatment.
The leading Hepatitis D Companies such as Vir Biotechnology, Inc./Alnylam Pharmaceuticals, Bluejay Therapeutics, Inc., Ribocure Pharmaceuticals AB, Assembly Biosciences, Shanghai HEP Pharmaceutical Co., Ltd., Huahui Health and others.
Promising Hepatitis D Pipeline Therapies such as Brelovitug 300 mg, lonafarnib, Ritonavir, Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa), hepalatide, Peginterferon Lambda-1a and others.

Stay ahead with the most recent pipeline outlook for Hepatitis D. Get insights into clinical trials, emerging therapies, and leading companies with Hepatitis D @ Hepatitis D Treatment Drugs

Hepatitis D Emerging Drugs Profile

Tobevibart + Elebsiran: Vir Biotechnology/ Alnylam Pharmaceuticals

Tobevibart is an investigational broadly neutralizing monoclonal antibody targeting the hepatitis B surface antigen. It is designed to inhibit the entry of hepatitis B and hepatitis delta viruses into hepatocytes, and to reduce the level of circulating viral and subviral particles in the blood. Tobevibart, which incorporates Xencor’s Xtend™ and other Fc technologies, has been engineered to have an extended half-life and was identified using Vir Biotechnology’s proprietary monoclonal antibody discovery platform. Elebsiran is an investigational hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) designed to degrade hepatitis B virus RNA transcripts and limit the production of hepatitis B surface antigen. Current data indicates that it has the potential to have direct antiviral activity against hepatitis B virus and hepatitis delta virus. It is the first asset in Vir Biotechnology’s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical studies. Currently, this combination drug product is in Phase III stage of its development for the treatment of Hepatitis D.

Brelovitug: Bluejay Therapeutics

Brelovitug is an investigational, highly potent, pan-genotypic, fully human IgG1 mAb that targets the anti-HBsAg on both the HDV and the HBV. Brelovitug is designed to neutralize and remove hepatitis B and hepatitis D virions and deplete HBsAg-containing subviral particles, which gives brelovitug a potentially advantageous safety profile and makes it a potentially efficacious treatment for CHD, a condition with urgent unmet medical need. In addition, brelovitug has shown immunomodulatory functions in CHB patients, which may help to reconstitute antiviral immunity and contribute to functional cure for CHB when combined with other agents. Currently, the drug is in the Phase II/III stage of its development for the treatment of Hepatitis D.

RBD1016: Ribocure Pharmaceuticals AB

RBD1016 is a GalNAc-siRNA drug independently developed by Ribo based on its proprietary GalNAc-siRNA platform, targeting the X gene of hepatitis B virus. It inhibits all four HBV transcripts through the RNA interference mechanism, and can simultaneously inhibit HBV DNA replication, reduce cccDNA and integrate DNA derived HBsAg and other antigens. RBD1016 demonstrates well-tolerated safety profile in Phase I study including both healthy subjects and patients with CHB infection. RBD1016 shows a highly efficient long-acting effect of reducing the HBsAg in patients. Currently, the drug is in Phase II stage of its development for the treatment of Hepatitis D.

The Hepatitis D Pipeline Report Provides Insights into-

The report provides detailed insights about companies that are developing therapies for the treatment of Hepatitis D with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatitis D Treatment.
Hepatitis D Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hepatitis D Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hepatitis D market

Explore groundbreaking therapies and clinical trials in the Hepatitis D Pipeline. Access DelveInsight’s detailed report now! @ New Hepatitis D Drugs

Hepatitis D Companies

Vir Biotechnology, Inc./Alnylam Pharmaceuticals, Bluejay Therapeutics, Inc., Ribocure Pharmaceuticals AB, Assembly Biosciences, Shanghai HEP Pharmaceutical Co., Ltd., Huahui Health and others.

Hepatitis D pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Hepatitis D Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Unveil the future of Hepatitis D Treatment. Learn about new drugs, Hepatitis D Pipeline developments, and key companies with DelveInsight’s expert analysis @ Hepatitis D Market Drivers and Barriers

Scope of the Hepatitis D Pipeline Report

Coverage- Global
Hepatitis D Companies- Vir Biotechnology, Inc./Alnylam Pharmaceuticals, Bluejay Therapeutics, Inc., Ribocure Pharmaceuticals AB, Assembly Biosciences, Shanghai HEP Pharmaceutical Co., Ltd., Huahui Health and others.
Hepatitis D Pipeline Therapies- Brelovitug 300 mg, lonafarnib, Ritonavir, Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa), hepalatide, Peginterferon Lambda-1a and others.
Hepatitis D Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Hepatitis D Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Hepatitis D Pipeline Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Hepatitis D Companies, Key Products and Unmet Needs

Table of Contents

Introduction
Executive Summary
Hepatitis D: Overview
Pipeline Therapeutics
Therapeutic Assessment
Hepatitis D– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Tobevibart + Elebsiran: Vir Biotechnology/ Alnylam Pharmaceuticals
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Brelovitug: Bluejay Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug Name: Company Name
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Hepatitis D Key Companies
Hepatitis D Key Products
Hepatitis D- Unmet Needs
Hepatitis D- Market Drivers and Barriers
Hepatitis D- Future Perspectives and Conclusion
Hepatitis D Analyst Views
Hepatitis D Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hepatitis-d-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hepatitis D Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Presbyopia Pipeline Grows With 10+ Prominent Companies Targeting Novel Treatment Approaches | DelveInsight

DelveInsight’s, “Presbyopia Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Presbyopia pipeline landscape. It covers the Presbyopia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Presbyopia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Presbyopia Pipeline. Dive into DelveInsight’s comprehensive report today! @ Presbyopia Pipeline Outlook

Key Takeaways from the Presbyopia Pipeline Report

In June 2025, Ocuphire Pharma Inc. announced a Phase 3 Study of the Safety and Efficacy of Nyxol (Phentolamine Ophthalmic Solution 0.75%) as a Single Agent and With Adjunctive Low-Dose Pilocarpine Hydrochloride Ophthalmic Solution 0.4% in Subjects With Presbyopia.
In June 2025, Orasis Pharmaceuticals Ltd. conducted a study is to evaluate the safety of CSF-1 compared with vehicle in presbyopic subjects. Subjects will be treated for at least 6 weeks.
DelveInsight’s Presbyopia Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Presbyopia treatment.
The leading Presbyopia Companies such as Visus Therapeutics, Glaukos Corporation, Cellix Bio, Orasis Pharmaceuticals, Cellix Bio and others.
Promising Presbyopia Pipeline Therapies such as Phentolamine Ophthalmic Solution 0.75%, Pilocarpine, Pilocarpine HCl, UNR844-Cl, CSF-1, AGN-190584, Pilocarpine Ophthalmic, Aceclidine, Brimonidine and others.

Stay ahead with the most recent pipeline outlook for Presbyopia. Get insights into clinical trials, emerging therapies, and leading companies with Presbyopia @ Presbyopia Treatment Drugs

Presbyopia Emerging Drugs Profile

LNZ100: Lenz Therapeutics

LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine, a selective muscarinic receptor agonist. It works by constricting the pupil, creating a pinhole effect that improves near vision. Unlike other pupil-constricting agents, aceclidine has a unique mechanism of action that decouples the miotic effect from the stimulation of the ciliary muscle, reducing the risk of myopic shift and accompanying brow ache. This allows LNZ100 to provide a broad patient population with a long-lasting and efficient treatment for presbyopia, a condition characterized by the gradual hardening of the lens and decline in near vision with age. US Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for LNZ100 for the treatment of presbyopia. Currently, the drug is in registration stage of its clinical trial for the treatment of presbyopia.

GLK-302: Glaukos Corporation

Glaukos Corporation is developing GLK-302, a sterile ophthalmic topical cream containing the active ingredient pilocarpine, for the treatment of presbyopia. GLK-302 is designed to be applied to the eyelid, allowing the pilocarpine to be delivered through the dermis to the eye. The mechanism of action involves pilocarpine, a muscarinic acetylcholine receptor agonist, which acts on the M3 and M1 receptors in the eye to cause pupillary constriction and increase the depth of focus, thereby improving near visual acuity in presbyopic patients without significantly deteriorating distance vision. Currently, the drug is in Phase II stage of its clinical trial for the treatment of presbyopia.

The Presbyopia Pipeline Report Provides Insights into-

The report provides detailed insights about companies that are developing therapies for the treatment of Presbyopia with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Presbyopia Treatment.
Presbyopia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Presbyopia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Presbyopia market

Explore groundbreaking therapies and clinical trials in the Presbyopia Pipeline. Access DelveInsight’s detailed report now! @ New Presbyopia Drugs

Presbyopia Companies

Visus Therapeutics, Glaukos Corporation, Cellix Bio, Orasis Pharmaceuticals, Cellix Bio and others.

Presbyopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Presbyopia Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Unveil the future of Presbyopia Treatment. Learn about new drugs, Presbyopia Pipeline developments, and key companies with DelveInsight’s expert analysis @ Presbyopia Market Drivers and Barriers

Scope of the Presbyopia Pipeline Report

Coverage- Global
Presbyopia Companies- Visus Therapeutics, Glaukos Corporation, Cellix Bio, Orasis Pharmaceuticals, Cellix Bio and others.
Presbyopia Pipeline Therapies- Phentolamine Ophthalmic Solution 0.75%, Pilocarpine, Pilocarpine HCl, UNR844-Cl, CSF-1, AGN-190584, Pilocarpine Ophthalmic, Aceclidine, Brimonidine and others.
Presbyopia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Presbyopia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Presbyopia Pipeline Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Presbyopia Companies, Key Products and Unmet Needs

Table of Contents

Introduction
Executive Summary
Presbyopia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Presbyopia – DelveInsight’s Analytical Perspective
Late Stage Products (Registration)
LNZ100: Lenz Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
GLK-302: Glaukos Corporation
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug Name: Company Name
Preclinical Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Presbyopia – Collaborations Assessment- Licensing / Partnering / Funding
Presbyopia – Unmet Needs
Presbyopia – Market Drivers and Barriers
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Presbyopia Pipeline Grows With 10+ Prominent Companies Targeting Novel Treatment Approaches | DelveInsight

Adrenocortical Carcinoma Pipeline Therapeutics Gets a Boost With 20+ Active Pharma Players | DelveInsight

DelveInsight’s, “Adrenocortical Carcinoma Pipeline Insight 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Adrenocortical Carcinoma pipeline landscape. It covers the Adrenocortical Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Adrenocortical Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Adrenocortical Carcinoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Adrenocortical Carcinoma Pipeline Outlook

Key Takeaways from the Adrenocortical Carcinoma Pipeline Report

In May 2025, Corcept Therapeutics conducted a study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.
DelveInsight’s Adrenocortical Carcinoma Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Adrenocortical Carcinoma treatment.
The leading Adrenocortical Carcinoma Companies such as Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech and others.
Promising Adrenocortical Carcinoma Pipeline Therapies such as Pembrolizumab, Sunitinib, OSI-906, Iressa (ZD1839), Osilodrostat, TKM-080301, Axitinib, Dostarlimab, Chemotherapy, Ipilimumab, Nivolumab and others.

Stay ahead with the most recent pipeline outlook for Adrenocortical Carcinoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Adrenocortical Carcinoma Treatment Drugs

Adrenocortical Carcinoma Emerging Drugs Profile

Relacorilant: Corcept Therapeutics

Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor, the receptor for cortisol which is activated when cortisol levels are high. Relacorilant does not bind to the body’s other hormone receptors. Corcept is studying relacorilant as a potential treatment for a variety of serious disorders, including Cushing’s syndrome and advanced adrenal, ovarian and pancreatic cancer.

Ipilimumab: Bristol-Myers Squibb

Yervoy is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). CTLA-4 is a negative regulator of T-cell activity. Yervoy binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor infiltrating T-effector cells. Inhibition of CTLA-4 signaling can also reduce T-regulatory cell function, which may contribute to a general increase in T-cell responsiveness, including the anti-tumor immune response. The drug is in phase 2 of clinical trials for the treatment of adrenocortical carcinoma.

The Adrenocortical Carcinoma Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Adrenocortical Carcinoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Adrenocortical Carcinoma Treatment.
Adrenocortical Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Adrenocortical Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Adrenocortical Carcinoma market

Explore groundbreaking therapies and clinical trials in the Adrenocortical Carcinoma Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Adrenocortical Carcinoma Drugs

Adrenocortical Carcinoma Companies

Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech and others.

Adrenocortical Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Adrenocortical Carcinoma Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Unveil the future of Adrenocortical Carcinoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Adrenocortical Carcinoma Market Drivers and Barriers

Scope of the Adrenocortical Carcinoma Market Report

Coverage- Global
Adrenocortical Carcinoma Companies- Corcept Therapeutics, Bristol-Myers Squibb, Enterome, Exelixis/Ipsen, Genentech and others.
Adrenocortical Carcinoma Pipeline Therapies such as Pembrolizumab, Sunitinib, OSI-906, Iressa (ZD1839), Osilodrostat, TKM-080301, Axitinib, Dostarlimab, Chemotherapy, Ipilimumab, Nivolumab and others.
Adrenocortical Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Adrenocortical Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Adrenocortical Carcinoma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Adrenocortical Carcinoma Companies, Key Products and Unmet Needs

Table of Contents

Introduction
Executive Summary
Adrenocortical Carcinoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Adrenocortical Carcinoma– DelveInsight’s Analytical Perspective
Mid Stage Products (Phase II)
Ipilimumab: Bristol-Myers Squibb
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Relacorilant: Corcept Therapeutics
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Adrenocortical Carcinoma Key Companies
Adrenocortical Carcinoma Key Products
Adrenocortical Carcinoma- Unmet Needs
Adrenocortical Carcinoma- Market Drivers and Barriers
Adrenocortical Carcinoma- Future Perspectives and Conclusion
Adrenocortical Carcinoma Analyst Views
Adrenocortical Carcinoma Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Adrenocortical Carcinoma Pipeline Therapeutics Gets a Boost With 20+ Active Pharma Players | DelveInsight

Pancreatic Cancer Pipeline Appears Robust With 170+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s “Pancreatic Cancer Pipeline Insight, 2025,” report provides comprehensive insights about 170+ companies and 200+ pipeline drugs in Pthe ancreatic Cancer pipeline landscape. It covers the Pancreatic Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pancreatic Cancer Pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Pancreatic Cancer Pipeline Report to explore emerging therapies, key Pancreatic Cancer Companies, and future Pancreatic Cancer treatment landscapes @ Pancreatic Cancer Pipeline Outlook Report

Key Takeaways from the Pancreatic Cancer Pipeline Report

In June 2025, Exelixis announced a study to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
In June 2025, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins conducted a study is to determine the optimal dose of AGEN2373 that is safe when given in combination with balstilimab and Pancreatic GVAX Whole Cell Vaccine and evaluate the safety and clinical activity of balstilimab and AGEN2373 in combination with GVAX (Arm 1) or mKRASvax (Arm 2) in surgically resectable pancreatic adenocarcinoma.
In June 2025, Verastem Inc. organized a study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.
DelveInsight’s Pancreatic Cancer pipeline report depicts a robust space with 170+ active players working to develop 200+ pipeline therapies for Pancreatic Cancer treatment.
The leading Pancreatic Cancer Companies such as Fibrogen, AB Science, Eleison Pharmaceuticals LLC, Janssen Pharmaceuticals, CARsgen Therapeutics, Arcus Biosciences, Inc., Chia Tai Tianqing Pharmaceutical Group, Innovent Biologics, Amgen, Biomea Fusion, Prestige Biopharma Limited, Bristol-Myers Squibb, GlaxoSmithKline, Incyte Corporation, Helix BioPharma, Genentech, Inc., ENB Therapeutics, Carrick Therapeutics, Avenge Bio, DEKA Biosciences, Keymed Biosciences, Pfizer, Redx Pharma Plc, and AIM ImmunoTech Inc., and others.
Promising Pancreatic Cancer Pipeline Therapies such as Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004), and Gemcitabine, and others.

Stay ahead with the most recent pipeline outlook for Pancreatic Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Pancreatic Cancer Treatment Drugs

Pancreatic Cancer Emerging Drugs Profile

Pamrevlumab: FibroGen

Pamrevlumab is a potential first-in-class antibody being developed by FibroGen that inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. The U.S. Food and Drug Administration has granted Orphan Drug Designation, and Fast Track designation to Pamrevlumab for the treatment of patients with pancreatic cancer. Currently it is in Phase III stage of clinical trial evaluation to treat Pancreatic Cancer.

Masitinib: AB Science

Masitinib (AB-1010) is an investigational drug for the treatment of metastatic pancreatic cancer. The drug candidate is administered orally. It is an ATP-binding site competitor. The drug candidate acts by inhibiting wild-type forms of c-KIT, Fyn, Lyn tyrosine kinase and platelet-derived growth factor receptor alpha and beta. Masitinib is a selective inhibitor of the tyrosine kinase inhibitor that targets KIT. Currently being evaluated in the Phase III studies.

Glufosfamide: Eleison Pharmaceuticals LLC.

Glufosfamide combines the active part of ifosfamide, a member of a widely used class of chemotherapy drugs called as alkylators with a glucose molecule. Because of its glucose component and a tumor cell’s increased need for glucose, glufosfamide may be preferentially transported into tumors compared to most normal tissues. Inside cells, the linkage between glucose and the alkylator is cleaved to release the active drug. Currently the drug is being evaluated in Phase III for the treatment of Pancreatic Cancer.

Quemliclustat: Arcus Biosciences, Inc.

Quemliclustat is a potent and selective small molecule being developed by Arcus Biosciences. Inhibitor of CD73 that has been shown to block the production of adenosine. The reduction of adenosine restores immune function. The drug candidate is administered through intravenous and oral route. The drug candidate is currently in Phase III stage of clinical trial.

CT041: CARsgen Therapeutics

CT041 is a potential first in class autologous chimeric antigen receptor CAR T-cell product candidate that targets the protein CLDN18.2. CT041 targets the treatment of CLDN18.2 positive solid tumors with a primary focus on pancreatic cancer. The drug candidate presently is in Phase II stage.

DK210: DEKA Biosciences

DK210 (EGFR) is the first of several experimental therapeutics developed as part of Deka’s platform of molecules, which combines the cytokines full strength IL-2 and a high affinity IL-10. While IL-2 is known to be toxic, when coupled with IL-10, toxicity is not only reduced but its potency is increased, thereby creating a more tolerable and effective treatment for patients. It is the first of several experimental therapeutics in Deka’s platform of molecules which are being developed to treat both cancer and inflammatory diseases. These therapeutics, known as DiakinesTM, involve coupling two cytokines together onto a single chain variable fragment (scFv) targeting system to enhance their precision in targeting specific tissues. Furthermore, the scFv scaffold used in the DiakineTM platform also improves efficacy, safety and manufacturability of each treatment. The drug candidate presently is in Phase I stage for the treatment of pancreatic cancer.

CT7001: Carrick Therapeutics

Samuraciclib is the most advanced CDK7 inhibitor in clinical development. Inhibiting CDK7 is a promising therapeutic strategy in cancer as CDK7 regulates the transcription of cancer-causing genes, promotes uncontrolled cell cycle progression and promotes resistance to anti-hormone therapy. Samuraciclib has demonstrated a favorable safety profile and encouraging efficacy in early clinical studies. In addition to the above studies, samuraciclib has further potential in prostate, pancreatic, ovarian and colorectal cancers. Samuraciclib has been granted Fast Track designation from the U.S. Food and Drug Administration (FDA) for use in combination with fulvestrant for the treatment of CDK4/6i resistant HR+, HER2- advanced breast cancer. Carrick is collaborating with Roche, Menarini Group and Arvinas/Pfizer to evaluate novel combinations of samuraciclib with Roche’s oral SERD giredestrant, Menarini Group’s oral SERD elacestrant, and Arvinas/Pfizer’s proteolysis targeting chimera (PROTAC) Estrogen Receptor degrader vepdegestrant (ARV-471) in late-stage CDK4/6i resistant HR+, HER2- metastatic breast cancer. Currently the drug is in preclinical stage of its development for the treatment of pancreatic cancer.

The Pancreatic Cancer Pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Pancreatic Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Cancer treatment.
Pancreatic Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Pancreatic Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic Cancer market.

Explore groundbreaking therapies and clinical trials in the Pancreatic Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Pancreatic Cancer Drugs

Pancreatic Cancer Companies

Fibrogen, AB Science, Eleison Pharmaceuticals LLC, Janssen Pharmaceuticals, CARsgen Therapeutics, Arcus Biosciences, Inc., Chia Tai Tianqing Pharmaceutical Group, Innovent Biologics, Amgen, Biomea Fusion, Prestige Biopharma Limited, Bristol-Myers Squibb, GlaxoSmithKline, Incyte Corporation, Helix BioPharma, Genentech, Inc., ENB Therapeutics, Carrick Therapeutics, Avenge Bio, DEKA Biosciences, Keymed Biosciences, Pfizer, Redx Pharma Plc, and AIM ImmunoTech Inc., and others

Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Pancreatic Cancer Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Unveil the future of Pancreatic Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Pancreatic Cancer Market Drivers and Barriers

Scope of the Pancreatic Cancer Pipeline Report

Coverage- Global
Pancreatic Cancer Companies- Fibrogen, AB Science, Eleison Pharmaceuticals LLC, Janssen Pharmaceuticals, CARsgen Therapeutics, Arcus Biosciences, Inc., Chia Tai Tianqing Pharmaceutical Group, Innovent Biologics, Amgen, Biomea Fusion, Prestige Biopharma Limited, Bristol-Myers Squibb, GlaxoSmithKline, Incyte Corporation, Helix BioPharma, Genentech, Inc., ENB Therapeutics, Carrick Therapeutics, Avenge Bio, DEKA Biosciences, Keymed Biosciences, Pfizer, Redx Pharma Plc, and AIM ImmunoTech Inc., and others.
Pancreatic Cancer Pipeline Therapies- Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine, and others.
Pancreatic Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Pancreatic Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Pancreatic Cancer drug development? Find out in DelveInsight’s exclusive Pancreatic Cancer Pipeline Report—access it now! @ Pancreatic Cancer Emerging Drugs and Major Companies

Table of Contents

Introduction
Executive Summary
Pancreatic Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Pancreatic Cancer – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Pamrevlumab: FibroGen
Drug profiles in the detailed report…..
Mid-Stage Products (Phase II)
CT041: CARsgen Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
DK210: DEKA Biosciences
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug: Company Name
Drug profiles in the detailed report…..
Inactive Products
Pancreatic Cancer Key Companies
Pancreatic Cancer Key Products
Pancreatic Cancer- Unmet Needs
Pancreatic Cancer- Market Drivers and Barriers
Pancreatic Cancer- Future Perspectives and Conclusion
Pancreatic Cancer Analyst Views
Pancreatic Cancer Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pancreatic Cancer Pipeline Appears Robust With 170+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Metastatic Prostate Cancer Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Metastatic Prostate Cancer Pipeline Insight, 2025” report provides comprehensive insights about 80+ companies and 85+ pipeline drugs in Metastatic Prostate Cancer pipeline landscape. It covers the Metastatic Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Prostate Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Metastatic Prostate Cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Metastatic Prostate Cancer Pipeline Outlook

Key Takeaways from the Metastatic Prostate Cancer Pipeline Report

In June 2025, Merck Sharp & Dohme LLC announced substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC).
In June 2025, AstraZeneca conducted a Phase I/II study of AZD0754 autologous CAR T-cell therapy administered intravenously to participants with metastatic prostate cancer. The study is intended to assess the safety, cellular kinetics, pharmacodynamics, preliminary efficacy, and feasibility of manufacturing AZD0754 for patients with metastatic prostate cancer.
In June 2025, Aragon Pharmaceuticals Inc. conducted a study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.
In June 2025, Janssen Biotech Inc. organized a study is to show that abiraterone acetate plus prednisone added to the current standard of care, gonadotropin-releasing hormone (GnRH) decreases prostate specific antigen (PSA) and prolongs the time until it is evident that the cancer has grown. Additionally, safety information about abiraterone acetate in combination with prednisone will be collected. This will include looking at what side effects occur, how often they occur, and for how long they last.
DelveInsight’s Metastatic Prostate Cancer Pipeline report depicts a robust space with 80+ active players working to develop 85+ pipeline therapies for Metastatic Prostate Cancer treatment.
The leading Metastatic Prostate Cancer Companies such as Merck, AstraZeneca, Syntrix Pharmaceuticals, Cardiff Oncology, Janux Therapeutics, ORIC Pharmaceuticals, Inc, Lantheus, Eli Lilly and Company, Madison Vaccines, Exelixis, Laekna Therapeutics, Regeneron Pharmaceuticals, Zenith Epigenetics, Phosplatin Therapeutics, MacroGenics, Modra Pharmaceuticals, RedHill Biopharma, DexTech Medical, Debiopharm, Astellas Pharma, Arvinas, Orion Corporation, CellCentric, Karyopharm Therapeutics, Corcept Therapeutics, OncoC4, Inmune Bio, Celcuity and others.
Promising Metastatic Prostate Cancer Pipeline Therapies such as Enzalutamide, Cabazitaxel, Ifinatamab Deruxtecan, MK-5684, Aflibercept, HLD-0915, Prednisone, Quinacrine, SR31747A anad others.

Stay ahead with the most recent pipeline outlook for Metastatic Prostate Cancer. Get insights into clinical trials, emerging therapies, and leading companies with Metastatic Prostate Cancer @ Metastatic Prostate Cancer Treatment Drugs

Metastatic Prostate Cancer Emerging Drugs Profile

Opevesostat: Merck

Opevesostat is an oral, non-steroidal and selective inhibitor of the CYP11A1 enzyme discovered and developed by Orion for the treatment of hormone-dependent cancers, such as prostate cancer. By inhibiting CYP11A1 enzyme activity, ODM-208 is designed to suppress the production of all steroid hormones and their precursors that may activate the androgen receptor signaling pathway. Currently, the drug is in Phase III stage of its development for the treatment of Metastatic Prostate Cancer.

AZD5305: AstraZeneca

AZD5305 is a highly potent and selective inhibitor of PARP1 with 500-fold selectivity for PARP1 over PARP2. When PARP1 is inhibited, it leads to the accumulation of DNA damage, particularly in cells lacking functional HRR pathways. This results in cell death due to the inability to repair critical DNA lesions. AZD5305 inhibits growth in cells with deficiencies in DNA repair, with minimal/no effects in other cells. Currently, the drug is in Phase III stage of its development for the treatment of Metastatic Prostate Cancer.

SX-682: Syntrix Pharmaceuticals

SX-682 is a potent small-molecule dual-inhibitor of CXCR1 and CXCR2, chemokine receptors pivotal to myeloid cell suppression of cancer surveillance by the adaptive immune system. By blocking the CXCR1/2 pathway, SX-682 inactivates immunosuppressive myeloid cells, thereby cutting off “at the source” dozens of downstream pro-tumor mechanisms mediated by these cells. The inactivation of suppressive myeloid cells liberates effector cells to kill and eliminate cancer cells. Currently, the drug is in Phase II stage of its development for the treatment of Metastatic Prostate Cancer.

Onvansertib: Cardiff Oncology

Onvansertib is a first-in-class, third generation, highly selective, oral Polo like Kinase 1 (PLK1) inhibitor, that is designed to target and inhibit cancer cell division (mitosis). It is an orally bioavailable, adenosine triphosphate (ATP) competitive inhibitor of polo-like kinase 1 (PLK1; PLK-1; STPK13), with potential antineoplastic activity. Upon administration, Onvansertib selectively binds to and inhibits PLK1, which disrupts mitosis and induces selective G2/M cell-cycle arrest followed by apoptosis in PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase that is crucial for the regulation of mitosis, and plays a key role in tumor cell proliferation. PLK1 expression is upregulated in a variety of tumor cell types and high expression is associated with increased aggressiveness and poor prognosis. Currently, the drug is in Phase II stage of its development for the treatment of Metastatic Prostate Cancer.

JANX007: Janux Therapeutics

JANX007 is lead novel Tumor Activated T Cell Engager (TRACTr). JANX007 is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of tumors and is in the clinic for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The company designed PSMA-TRACTr drug candidate as a single-masked TRACTr in which the PSMA-binding domain is unmasked. The T cell-specific binding domain (CD3e) is masked to help minimize CRS. Currently, the drug is in Phase I stage of its development for the treatment of Metastatic Prostate Cancer.

ORIC-944: ORIC Pharmaceuticals, Inc

ORIC-944 is a potent and selective allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the embryonic ectoderm development (EED) subunit that demonstrates best-in-class drug properties in preclinical studies, including potency, solubility, and pharmacokinetics, with half-life supporting once daily dosing. ORIC-944 was initially evaluated as a single agent in a Phase Ib trial in patients with advanced prostate cancer and demonstrated potential best-in-class drug properties, including clinical half-life of approximately 20 hours, robust target engagement and a favorable safety profile. Currently, the drug is in Phase I stage of its development for the treatment of Metastatic Prostate Cancer.

The Metastatic Prostate Cancer Pipeline Report Provides Insights into-

The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Prostate Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Prostate Cancer Treatment.
Metastatic Prostate Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Metastatic Prostate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Prostate Cancer market

Explore groundbreaking therapies and clinical trials in the Metastatic Prostate Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Metastatic Prostate Cancer Drugs

Metastatic Prostate Cancer Companies

Merck, AstraZeneca, Syntrix Pharmaceuticals, Cardiff Oncology, Janux Therapeutics, ORIC Pharmaceuticals, Inc, Lantheus, Eli Lilly and Company, Madison Vaccines, Exelixis, Laekna Therapeutics, Regeneron Pharmaceuticals, Zenith Epigenetics, Phosplatin Therapeutics, MacroGenics, Modra Pharmaceuticals, RedHill Biopharma, DexTech Medical, Debiopharm, Astellas Pharma, Arvinas, Orion Corporation, CellCentric, Karyopharm Therapeutics, Corcept Therapeutics, OncoC4, Inmune Bio, Celcuity and others.

Metastatic Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Metastatic Prostate Cancer Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Unveil the future of Metastatic Prostate Cancer Treatment. Learn about new drugs, Metastatic Prostate Cancer Pipeline developments, and key companies with DelveInsight’s expert analysis @ Metastatic Prostate Cancer Market Drivers and Barriers

Scope of the Metastatic Prostate Cancer Pipeline Report

Coverage- Global
Metastatic Prostate Cancer Companies- Merck, AstraZeneca, Syntrix Pharmaceuticals, Cardiff Oncology, Janux Therapeutics, ORIC Pharmaceuticals, Inc, Lantheus, Eli Lilly and Company, Madison Vaccines, Exelixis, Laekna Therapeutics, Regeneron Pharmaceuticals, Zenith Epigenetics, Phosplatin Therapeutics, MacroGenics, Modra Pharmaceuticals, RedHill Biopharma, DexTech Medical, Debiopharm, Astellas Pharma, Arvinas, Orion Corporation, CellCentric, Karyopharm Therapeutics, Corcept Therapeutics, OncoC4, Inmune Bio, Celcuity and others.
Metastatic Prostate Cancer Pipeline Therapies- Enzalutamide, Cabazitaxel, Ifinatamab Deruxtecan, MK-5684, Aflibercept, HLD-0915, Prednisone, Quinacrine, SR31747A anad others.
Metastatic Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Metastatic Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Metastatic Prostate Cancer Pipeline Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Metastatic Prostate Cancer Companies, Key Products and Unmet Needs

Table of Contents

Introduction
Executive Summary
Metastatic Prostate Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Metastatic Prostate Cancer– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Opevesostat: Merck
Mid Stage Products (Phase II)
SX-682: Syntrix Pharmaceuticals
Early Stage Products (Phase I)
JANX007: Janux Therapeutics
Preclinical and Discovery Stage Products
Drug Name: Company Name
Inactive Products
Metastatic Prostate Cancer Key Companies
Metastatic Prostate Cancer Key Products
Metastatic Prostate Cancer- Unmet Needs
Metastatic Prostate Cancer- Market Drivers and Barriers
Metastatic Prostate Cancer- Future Perspectives and Conclusion
Metastatic Prostate Cancer Analyst Views
Metastatic Prostate Cancer Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Prostate Cancer Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Top Granada Hills, CA Realtor Reveals Why Homebuyers Face Higher Costs Every Year They Delay Purchase

Granada Hills, CA – Vic Markarian, founder of the Markarian Realty Group, has released an eye-opening analysis demonstrating why potential homebuyers who postpone their purchase decisions face increasingly higher costs with each passing year. This timely insight comes as many prospective buyers remain hesitant amid changing market conditions.

The report draws on data from the quarterly Home Price Expectations Survey, aggregating forecasts from over 100 housing experts who unanimously project continued home value appreciation through at least 2029.

“The old saying that the best time to buy was yesterday, and the second best time is today, actually holds substantial truth in our current market,” explains Vic Markarian, real estate agent. “What many buyers fail to recognize is that waiting for ‘perfect’ conditions often means paying significantly more in the long run.” This perspective has made Markarian one of the top Realtors in Granada Hills, CA for buyers seeking clear, data-driven guidance.

For those considering postponing their purchase, Markarian’s analysis reveals that even modest 3-4% annual appreciation rates can translate to substantial additional costs. A property valued at $400,000 today could reach nearly $480,000 by 2030—representing $79,000 in missed equity growth for those who delay. Working with an experienced Realtor agent in Granada Hills, CA can help buyers understand these financial implications in the context of their personal circumstances.

“Time in the market consistently outperforms attempts to time the market perfectly,” Markarian notes. His team’s approach centers on helping clients explore practical solutions, from starter homes in more affordable Los Angeles neighborhoods to creative mortgage options. This client-focused strategy has established them as some of the most sought-after real estate agents in Granada Hills, CA.

The Markarian Realty Group brings together highly rated professionals who work collaboratively on each transaction, earning them recognition as leading Realtors in Granada Hills, CA dedicated to achieving optimal outcomes for buyers.

To discuss your homebuying options or receive a personalized market analysis, contact Vic Markarian and his team at http://www.markarianrealty.com/ and take the first step toward building equity sooner rather than later.

Media Contact
Company Name: Vic Markarian Realty Group
Contact Person: Media Relations
Email: Send Email
Phone: +1 818 248 8668
Address:3237 N Verdugo Rd
City: Glendale
State: California 91208
Country: United States
Website: http://MarkarianRealty.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Granada Hills, CA Realtor Reveals Why Homebuyers Face Higher Costs Every Year They Delay Purchase

Colorectal Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Exelixis, Mirati Therapeutics, Merck Sharp

“Colorectal Cancer Pipeline Insights”

DelveInsight’s, “Colorectal Cancer – Pipeline Insight, 2025,” report provides comprehensive insights about 195+ companies and 200+ pipeline drugs in Colorectal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

According to DelveInsight, over 195 major companies are actively engaged in developing more than 200 therapeutic candidates for the treatment of colorectal cancer.

Colorectal Cancer Overview:

Colorectal cancer (CRC) is a malignancy that arises in the colon or rectum due to abnormal growth of glandular epithelial cells. It is broadly categorized into three types: sporadic, hereditary, and colitis-associated. Globally, the incidence of CRC is on the rise, driven by both genetic predisposition and environmental influences. Individuals with long-standing inflammatory bowel diseases such as ulcerative colitis or Crohn’s disease are at a heightened risk, with the likelihood increasing with age. Research highlights the significant roles of diet, lifestyle, family history, and chronic inflammation in CRC development.

CRC progresses through a multistep process, beginning with epithelial hyperplasia, advancing through stages of atypical hyperplasia and adenoma formation, and ultimately leading to carcinoma. This progression is fueled by carcinogens that induce DNA damage, triggering the transformation of normal cells into cancerous ones. Morphological stages include hyperplasia, adenomas, carcinoma in situ, and invasive carcinoma. In 1990, Fearon and Vogelstein introduced a model outlining the molecular events involved in CRC development. Subsequent studies have identified three primary molecular mechanisms: (i) chromosomal instability, commonly observed in familial adenomatous polyposis (FAP); (ii) mutations in mismatch repair (MMR) genes, as seen in Lynch syndrome and sporadic cases; and (iii) CpG island hypermethylation, which silences tumor suppressor genes. These pathways involve alterations in several critical genes, including APC, DCC, P53, K-ras, c-MYC, MCC, and MMR-related genes such as hMLH1, hMLH3, hMSH2, hMSH3, hMSH6, hPMS1, and hPMS2. Notably, these molecular changes often overlap, with many CRC cases exhibiting a combination of these mechanisms.

Request for a detailed insights report on Colorectal Cancer pipeline insights

“Colorectal Cancer Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Colorectal Cancer Therapeutics Market.

Key Takeaways from the Colorectal Cancer Pipeline Report

DelveInsight’s Colorectal Cancer pipeline report depicts a robust space with 195+ active players working to develop 200+ pipeline therapies for Colorectal Cancer treatment.
In October 2025, U.S. regulators extended the evaluation period for Amgen’s LUMAKRAS (sotorasib) for second-line colorectal cancer (CRC) by three months, delaying a potential approval decision until January 17 of the following year. This extension also temporarily reduces the competitive pressure on Bristol Myers Squibb’s KRAS inhibitor, KRAZATI (adagrasib).
In June 2025, Bristol Myers Squibb announced that the US FDA granted accelerated approval for KRAZATI (adagrasib) in combination with cetuximab for adult patients with previously treated kras G12C-mutated locally advanced or metastatic colorectal cancer.
In April 2025, ENHERTU was approved in the US as the first tumor-agnostic HER2-directed therapy for patients with metastatic HER2-positive solid tumors, including colorectal cancer, who had been previously treated.
In November 2023, the US FDA approved Takeda’s FRUZAQLA for adults with metastatic colorectal cancer who had previously received specific chemotherapies and targeted therapies.
Key Colorectal Cancer companies such as Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences, Inc, Neogap Therapeutics AB, Criterium, Inc, Daiichi Sankyo, Inc, Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma, Ltd., BeyondBio Inc., Shanghai Henlius Biotech, Rottapharm Biotech, Innovative Cellular Therapeutics Inc., BioNTech SE, and others are evaluating new drugs for Colorectal Cancer to improve the treatment landscape.
Promising Colorectal Cancer pipeline therapies in various stages of development include XL092, Adagrasb, Olaparib, DS-8201, Ompenaclid, LYL845, RG6286, and others.

Colorectal Cancer Pipeline Analysis

The report provides insights into:

The report provides detailed insights into the key companies that are developing therapies in the Colorectal Cancer Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Colorectal Cancer treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Colorectal Cancer market.

Download our free sample page report on Colorectal Cancer pipeline insights

Colorectal Cancer Emerging Drugs

XL092 : Exelixis
Adagrasb : Mirati Therapeutics
Olaparib : Merck Sharp & Dohme LLC/Astrazeneca
DS-8201: Daiichi Sankyo
Ompenaclid: Inspirna
LYL845: Lyell Immunopharma
RG6286: Genentech

Colorectal Cancer Companies

There are over 195 key companies working on developing therapies for Colorectal Cancer. Among them, Exelixis has drug candidates for Colorectal Cancer in the most advanced stage, Phase III.

DelveInsight’s report covers around 200+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Colorectal Cancer Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Colorectal Cancer Therapies and Key Companies: Colorectal Cancer Clinical Trials and advancements

Colorectal Cancer Pipeline Therapeutic Assessment

• Colorectal Cancer Assessment by Product Type

• Colorectal Cancer By Stage

• Colorectal Cancer Assessment by Route of Administration

• Colorectal Cancer Assessment by Molecule Type

Download Colorectal Cancer Sample report to know in detail about the Colorectal Cancer treatment market @ Colorectal Cancer Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Colorectal Cancer Current Treatment Patterns

4. Colorectal Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Colorectal Cancer Late-Stage Products (Phase-III)

7. Colorectal Cancer Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Colorectal Cancer Discontinued Products

13. Colorectal Cancer Product Profiles

14. Colorectal Cancer Key Companies

15. Colorectal Cancer Key Products

16. Dormant and Discontinued Products

17. Colorectal Cancer Unmet Needs

18. Colorectal Cancer Future Perspectives

19. Colorectal Cancer Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Colorectal Cancer Pipeline Reports Offerings

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Colorectal Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Exelixis, Mirati Therapeutics, Merck Sharp